Evaluating the Efficacy of Dry Eye (DE) Disease Treatment Using Novel Tear Film Imager (TFI)

80 subjects will be enrolled , 40 of which with positive signs and symptoms of Dry eye and 40 healthy subjects without sign and no symptoms of Dry eye. Healthy and Dry eye groups will be age- matched.

Over a period of 4 weeks, the subjects diagnosed with dry eye will be treated and as follows:

• Hylo-comod artificial tears (0.1 % sodium hyaluronate) 8 times a day for 4 weeks
• Coll STERODEX (Dexamethasone sodium phosphate 0.1% eye drops) 3 times a day for 2 weeks Healthy subjects will not receive any treatment.

Both groups will be examined at baseline and 4 weeks after baseline measurement.

Treatment results will be measured by both traditional methods and by Tear Film Imager.

Inclusion criteria

• Signed informed consent form.
• Be at least 18 years of age at the time of enrollment of either sex or any race.
• Best corrected visual acuity (BCVA) of 0.7 logMAR (ie, 20/100 vision) or better in each eye as measured using a Snellen chart
• Intraocular pressure (IOP) in the range of 5 to 22 mmHg in both eyes.
• DE subjects will be enrolled if they manifest symptoms (OSDI >=13) and signs of clinically active dry eye disease in either eye, by at least one of:

• Corneal fluorescein staining - at least severe in one section or moderate at two
• TBUT =< 10 sec
• Schirmer wetting of less than 10 mm in 5 min (with anesthesia).
• Control will be enrolled if they manifest NO symptoms (OSDI <13) and NO signs of clinically active dry eye disease in either eye, by meeting all the following criteria's:

• Corneal fluorescein staining - negative
• TBUT > 10
• Schirmer wetting of more than 10 mm in 5 min (with anesthesia).
• A negative urine pregnancy test if female of childbearing potential.

Exclusion criteria

• Any ocular condition that could affect study parameters (glaucoma, nystagmus, keratoconus, follicular conjunctivitis, iritis or post LASIK, LASEK or PRK).
• Have had any ocular infection within the last 30 days and/or have preauricular lymphadenopathy.
• Any significant illness that could be expected to interfere with study parameters.
• Use of any investigational product or device within one month prior to Visit 1 or during the study period.
• Concomitant use of any prohibited medication (antihistamines, corticosteroids, all ocular medications or anti-allergic therapies) during the trial.
• Any history of, positive HIV, hepatitis B, C, or evidence of acute active hepatitis A (anti HAV IgM), Any known history of iritis/uveitis, glaucoma, or other chronic ophthalmologic disorder other than allergic conjunctivitis.
• History of any ocular surgical procedure within 3 months prior to Visit 1.